ornithine phenylacetate

DRUG2 trials

Sponsors

William Lee, Ocera Therapeutics, Inc.

Conditions

Acute Episode of Overt Hepatic EncephalopathyAcute Liver FailureAcute Liver InjuryHepatic Encephalopathy

Phase 2

Safety Study of Ornithine Phenylacetate to Treat Patients With Acute Liver Failure/Severe Acute Liver Injury

CompletedNCT01548690

William LeeAcute Liver Failure, Acute Liver Injury

Start: 2012-06-30End: 2017-02-23Updated: 2018-10-30

Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE)

CompletedNCT01966419

Ocera Therapeutics, Inc.Acute Episode of Overt Hepatic Encephalopathy, Hepatic Encephalopathy

Start: 2014-01-07End: 2016-12-29Updated: 2021-09-16

Related Papers

Pharmacokinetics/pharmacodynamics of L‐ornithine phenylacetate in overt hepatic encephalopathy and the effect of plasma ammonia concentration reduction on clinical outcomes

Clinical and Translational Science2022-03-0319 citations

Efficacy and Safety of Ornithine Phenylacetate for Treating Overt Hepatic Encephalopathy in a Randomized Trial

Clinical Gastroenterology and Hepatology2020-10-1664 citations